

Osteolabs to present new clinical data from over 2.400 OsteoTest routine samples at the WCO-IOF-ESCEO Congress

New data fully supporting potential for OsteoTest to qualify as new universal diagnostic method for early osteoporosis risk assessment and therapeutic control

Kiel (Germany), April 9, 2024 – Osteolabs GmbH, an innovative diagnostic company applying its proprietary CIM (Calcium isotope marker) technology for the early detection of Calcium-related metabolic bone diseases affecting over 1 billion patients worldwide, announced today an oral and poster presentation at the world’s leading clinical conference on bone, joint and muscle health (WCO-IOF-ESCEO) taking place in London from April 11-14, 2024 highlighting new clinical data from over 2.400 OsteoTest routine samples.

The abstract entitled “CALCIUM (CA) ISOTOPE COMPOSITION IN SERUM AND URINE FOR THE ASSESSMENT OF BONE CALCIUM BALANCE (BCAB) – RESULTS FROM A POST-MARKET SURVEILLANCE CLINICAL FOLLOW-UP STUDY ON 2409 PARTICIPANTS” will be presented by **Professor Anton Eisenhauer** who is a **key inventor of the CIM technology and Osteolabs’ Chief Scientific Officer**. The related presentation will feature key results from a subset of more than 2.400 samples, which were generated by Osteolabs as part of its clinical diagnostic routine analysis for over 5.000 OsteoTest samples so far.

“We are very happy to demonstrate that this larger set of routine clinical samples fully supports the potential for OsteoTest to qualify as a new universal diagnostic method for early osteoporosis risk assessment and therapeutic control,” said **Prof. Anton Eisenhauer**. “All our new results are in full accordance with earlier clinical validation data and related CIM threshold values for Bone Calcium Balance (BCaB).¹ Moreover, all diseases, therapies or diets, positively or negatively affecting the musculoskeletal metabolism, were sensitively reflected by a change of the CIM value in serum and urine.”

As part of the conference, Osteolabs is also proud to announce the joining of PRECCO (PRE-COMPETITIVE CONSORTIUM ON OSTEOPOROSIS AND BONE HEALTH), a new collaboration between the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the World Health Organization (WHO) to improve the epidemiology, screening, diagnosis, measurement, prevention, treatment, rehabilitation and monitoring of osteoporosis and fractures. More information on PRECCO could be found: <https://www.osteoporosis.foundation/who-esceo-agreement>

Details of the upcoming event:

24th Edition of the WCO-IOF-ESCEO Congress (London)

Oral presentation title: CALCIUM (CA) ISOTOPE COMPOSITION IN SERUM AND URINE FOR THE ASSESSMENT OF BONE CALCIUM BALANCE (BCAB) – RESULTS FROM A POST-MARKET SURVEILLANCE CLINICAL FOLLOW-UP STUDY ON 2409 PARTICIPANTS

Date and Time: April 13, 2024; 2-3 p.m.

Presenter: Prof. Anton Eisenhauer

References

¹ Eisenhauer A et al., Bone Reports 2019; 10:100200; DOI: <https://doi.org/10.1016/j.bonr.2019.100200>

For further information please contact:

Osteolabs GmbH

Kathrin Hagen (Öffentlichkeitsarbeit)

+49 431 990730

kh@osteolabs.de

About Osteolabs GmbH – www.osteolabs.de

Osteolabs GmbH is an innovative diagnostics company which was spun out from GEOMAR Helmholtz Centre for Ocean Research Kiel and the Helmholtz Association Berlin in 2018. The company deploys its proprietary CIM (Calcium isotope marker) technology for the early detection of Calcium-related metabolic bone diseases affecting over 1 billion patients worldwide with an initial focus on early risk determination of osteoporosis.